Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bryostatin 1 - GPC Biotech

Drug Profile

Bryostatin 1 - GPC Biotech

Alternative Names: BMY 45618; Bryol; NSC 339555

Latest Information Update: 11 Mar 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arizona State University
  • Developer GPC Biotech AG
  • Class Antidementias; Antineoplastics; Macrocyclic compounds; Neuroprotectants
  • Mechanism of Action Protein kinase C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Chronic lymphocytic leukaemia; Graft-versus-host disease; Malignant melanoma; Non-Hodgkin's lymphoma; Oesophageal cancer; Renal cancer

Most Recent Events

  • 09 Mar 2004 Discontinued - Phase-II for Cancer in United Kingdom (Parenteral)
  • 09 Mar 2004 Discontinued - Phase-II for Chronic lymphocytic leukaemia in USA (IV)
  • 09 Mar 2004 Discontinued - Phase-II for Malignant melanoma in Canada (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top